A unique COVID-19 case

Abstract

We present the case of a patient with granulomatosis with polyangiitis (GPA) treated with rituximab, who was diagnosed with coronavirus disease 2019 (COVID-19). Following an index hospitalization with apparent resolution of the infection, the patient was readmitted with clinical deterioration. While repeat serial real-time polymerase chain reaction (rt-PCR) from nasopharyngeal swabs were negative, a bronchoalveolar lavage (BAL) sample demonstrated persistent COVID-19 to be the etiologic factor. Administration of convalescent plasma led to remarkable recovery.

Keywords

COVID-19 / SARS-CoV-2 / GPA / Rituximab / Convalescent plasma

References

[1] Charles P, Terrier B, Perrodeau É, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Annals of the Rheumatic Diseases. 2018; 77(8): 1143-1149.

[2] Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China. Intensive Care Medicine. 2020; 46(2): 357-360. PMid:32025779. https://doi.org/10.1007/s00134-020-05954-2

[3] Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in False- Negative Rate of Reverse Transcriptase Polymerase Chain Reaction- Based SARS-CoV-2 Tests by Time since Exposure. Annals of Internal Medicine. M20-1495. 2020. PMid:32422057. https://doi.org/10.7326/M20-1495

[4] Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020; 323(18): 1843-1844. https://doi.org/10.1001/jama.2020.3786

[5] Haberman R, Axelrad J, Chen A, et al. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. New England Journal of Medicine. 2020; 383: 85-88. https://doi.org/10.1056/NEJMc2009567

[6] Guilpain P, Le Bihan C, Foulongne V, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Annals of the Rheumatic Disease. 217549. 2020. PMid:32312768. https://doi.org/10.1136/annrheumdis-2020-217549

[7] Barmettler S, Ong MS, Farmer JR, et al. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2018; 1(7): e184169. PMid:30646343. https://doi.org/10.1001/jamanetworkopen.2018.4169

[8] Guan Wj, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020; 382(18): 1708-1720.

[9] Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16): 1582-1589. https://doi.org/10.1001/jama.2020.4783

[10] Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020; 323(16): 1561-1562. PMid:32219429. https://doi.org/10.1001/jama.2020.4940

[11] Zeng QL, Yu ZJ, Gou JJ, et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. The Journal of Infectious Diseases. 2020; 222(1): 38-43. PMid:32348485. https://doi.org/10.1093/infdis/jiaa228

[12] Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. Journal of Medical Virology.

[13] Duan K, Liu B, Li C, et al.Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020; 117(17): 9490-9496. PMid:32253318. https://doi.org/10.1073/pnas.2004168117

[14] Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Lifethreatening COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(5): 460-470. https://doi.org/10.1001/jama.2020.10044